Daiichi Sankyo Submits Application for Approval of Levofloxacin Hydrate Injection in Japan

Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it submitted an application in Japan on October 28 to manufacture and market an injectable preparation of Levofloxacin Hydrate that incorporates the company’s new quinolone anti-bacterial agent.

Clinical trials have confirmed the injection’s excellent clinical efficacy against pneumonia and secondary chronic respiratory infections. Cravit®, an oral Levofloxacin Hydrate agent, already is a widely accepted treatment in formulations of 500mg and 250mg tablets and as a 10% fine granular preparation. The addition of an injectable version in Levofloxacin Hydrate lineup would contribute further to infectious disease treatment. – Daiichi Sankyo Company, Limited